In an interview with CEO Magazine, Marc Voigt, CEO of Immutep, discusses the company’s partnership with CATO SMS and the importance of choosing the right partner to support drug development programs. Immutep is a biotechnology company working primarily in the field of cancer. The two companies are collaborating on two clinical trials for treatments of breast and head and neck cancers. Read the full article.
